Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

NCT ID: NCT07130695

Last Updated: 2025-12-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-01
• Study Completion Date: 2029-10-31

Brief Summary

Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.

Detailed Description

Up to 15 participants will receive treatment with olutasidenib 150 mg by mouth twice daily for up to 2 years. Participants will be regularly monitored for toxicities, adverse events, quality of life (QOL), and disease status. Once off treatment, participants will continue to be followed for a maximum of 2 years from date of enrollment for survival endpoints

Conditions

Acute Myeloid Leukemia

Keywords

Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Olutasidenib Investigational Agent Administration

150 mg by mouth twice daily.

Group Type: EXPERIMENTAL

Olutasidenib Investigational Agent Administration

Intervention Type: DRUG

Twice daily olutasidenib maintenance therapy

Interventions

Olutasidenib Investigational Agent Administration

Twice daily olutasidenib maintenance therapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed non-acute promyelocytic isocitrate dehydrogenase (1 IDH1) mutant acute myeloid leukemia (AML). IDH1 mutation may be identified by NGS or PCR based methods and identified at time of diagnosis or any other time point prior to enrollment.
• Completed induction and/or consolidation intended as per treating physician to reach complete response (CR),complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), or morphologic leukemia free state (MLFS) at time of study enrollment Patients must be within 90 days of their last cycle of upfront therapy.
• Age ≥18 years
• Calculated creatinine clearance (by Cockroft-Gault) ≥30 mL/min
• Total bilirubin ≤2 × upper limit of normal (ULN) Note: patients with Gilbert's syndrome may be included if total bilirubin is ≤3 × ULN and direct bilirubin is ≤2 × ULN
• Serum aspartate aminotransferase/ alanine aminotransferase (AST/ALT) ≤3 × ULN
• Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2 or KPS >50%
• Able to take oral medications
• Women of childbearing potential must consent to effective contraception during study treatment and at least 6 months following the last dose. Effective methods of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double- barrier methods. (ie, combination of male condom with either cap, diaphragm or sponge with spermicide)
• Male participants who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug.

Exclusion Criteria

• History of hypersensitivity or allergic reaction to olutasidenib or its components
• Corrected Q-T interval (QTc) (Fredericia calculation) > 450 ms (after corrective action is taken)
• History of Torsades de Pointes
• Any gastrointestinal condition thought by the treating investigator to impair oral absorption of medication
• Stem cell transplant eligible and planned within 60 days of study start date in the opinion of the treating investigator
• Uncontrolled intercurrent illness or infection (those with controlled human immunodeficiency virus (HIV), hepatitis, or other chronic infections are eligible)
• Female participants who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
• Nursing women, women of childbearing potential with positive pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. (Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double-barrier methods)
• Male participants who intend to donate sperm during the course of this study or for 3 months after last dose
• Participants receiving, or are expected to require during the study, any concomitant medications that may interfere with efficacy, metabolism, or safety of the investigational agent, including drugs known to cause QT prolongation. for which drug interactions with olutasidenib would be prohibitory
• Concurrent chemotherapy for non-AML malignancy that is expected to interfere with the efficacy, metabolism, or safety of the agent under investigation
• Received non-intensive upfront therapy including hypomethylating agents (HMA) /Venetoclax based
• Currently receiving other targeted therapies or AML directed therapies, including but not limited to other IDH1 or IDH2 inhibitors, FMS-like tyrosine kinase 3 (FLT3) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors, menin inhibitors
• Other investigational agents in another clinical trial within 4 weeks prior to enrollment
• Systemic corticosteroids above physiologic replacement doses (10mg/day prednisone or equivalent), unless used to tread IDH differentiation syndrome or as part of a pre-specified protocol exception
• Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rigel Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Virginia Commonwealth University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keri Maher, DO

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonwealth University

Locations

Virginia Commonwealth University

Richmond, Virginia, United States

Countries

United States

Central Contacts

Massey IIT Research Operations

Role: CONTACT

Phone: 804-628-6430

Email: masseyepd@vcu.edu

Other Identifiers

MCC-25-22096

Identifier Type: -

Identifier Source: org_study_id